ライフサイエンスコーパス: hypoxemic

1 sly as normoxemic or a normoxemic patient as hypoxemic.

2 ys of IMV and in patients who are profoundly hypoxemic.

3 neonates who require BAS are typically more hypoxemic.

4 nd in group D, was neither hypertrophied nor hypoxemic.

5 chanical ventilation in patients who develop hypoxemic acute respiratory failure after abdominal surg

6 outcomes of immunocompromised patients with hypoxemic acute respiratory failure treated with high-fl

7 ompromised patients admitted to the ICU with hypoxemic acute respiratory failure, early noninvasive v

8 In immunocompromised patients with hypoxemic acute respiratory failure, high-flow nasal oxy

9 itically ill immunocompromised patients with hypoxemic acute respiratory failure.

10 itically ill immunocompromised patients with hypoxemic acute respiratory failure.

11 Immunocompromised patients with hypoxemic acute respiratory failure.

12 tality among immunocompromised patients with hypoxemic acute respiratory failure.

13 s included mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay.

14 ted effects of adjunctive corticosteroids in hypoxemic adults with M. pneumoniae pneumonia.

15 study, we have shown that ARDS patients were hypoxemic and monocytopenic within the first 48 h of ven

16 baseline physiological values with low-flow hypoxemic and normoxemic perfusion but not with low-flow

17 ons 45 (46%) were hypotensive, 23 (24%) were hypoxemic, and 29 (30%) were mixed.

18 ved across the bioenergetically more active, hypoxemic, and acidotic femoral circulation (P<0.05 vers

19 The unmatched, severely hypoxemic, and younger ECMO-treated patients had, howeve

20 in groups B and C, was hypertrophied but not hypoxemic; and in group D, was neither hypertrophied nor

21 Patients with hypoxemic ARF in the NPPV group had a significantly lowe

22 may only have a phenotype when the animal is hypoxemic at altitude.

23 Following RTN (Nmb) lesion, mice were hypoxemic at rest and were prone to severe apneas during

24 uring physical activity but are not severely hypoxemic at rest; (2) efficacy of LTOT in subjects with

25 where the heart is chronically perfused with hypoxemic blood.

26 ventricular free wall, which in group A, was hypoxemic but not hypertrophied; in groups B and C, was

27 t or failed intubation increases the risk of hypoxemic cardiopulmonary arrest and/or pulmonary aspira

28 he hypothalamo-pituitary-adrenal axis during hypoxemic challenges to homeostasis in a fashion similar

29 mproves exercise tolerance of normoxemic and hypoxemic chronic obstructive pulmonary disease (COPD) p

30 exercise testing in 27 patients with severe hypoxemic chronic obstructive pulmonary disease (COPD),

31 tudy in healthy volunteers showed that under hypoxemic conditions hepcidin is repressed and duodenal

32 oxide (NO) in the circulation, especially in hypoxemic conditions.

33 Eleven stable hypoxemic COPD patients (mean +/- SD: FEV1 = 1.00 +/- 0.

34 d dyspnea reductions in patients with severe hypoxemic COPD.

35 In the hypoxemic COVID-19 group, the primary outcome occurred i

36 ical open-label trial included patients with hypoxemic COVID-19 pneumonia requiring supplemental oxyg

37 d dendritic cells (pDCs), thereby underlying hypoxemic COVID-19 pneumonia with high penetrance.

38 oagulation-related bleeding in patients with hypoxemic COVID-19 pneumonia, identifying the lowest eff

39 genic bacteria, but also have a high risk of hypoxemic COVID-19 pneumonia.

40 ime to clinical improvement in patients with hypoxemic COVID-19 pneumonia; however, HD-PA resulted in

41 oxemia as candidate management strategies in hypoxemic critically ill patients.

42 side ICU should be further explored in other hypoxemic diseases and clinical settings aiming to prese

43 ed to 36 weeks' postmenstrual age, prolonged hypoxemic episodes during the first 2 to 3 months after

44 t were recorded at 3-minute intervals during hypoxemic episodes lasting 15 minutes to 2 hours.

45 The number of hypoxemic episodes lasting 2 minutes or longer per 100 h

46 sociation was significant only for prolonged hypoxemic episodes lasting at least 1 minute (relative r

47 The median number of hypoxemic episodes ranged from 0.8/day (interquartile ra

48 Hypoxemic episodes were associated with an estimated inc

49 mpared with the lowest decile of exposure to hypoxemic episodes, the adjusted relative risk of severe

50 s both occurrence and magnitude of potential hypoxemic events 30 minutes in the future, allowing it t

51 nts with BPD-PH, infants who died had longer hypoxemic events below 70% (145 s vs. 72 s; P = 0.01).

52 Using the duration of hypoxemic events below 70%, the areas under the ROC curv

53 The rate of hypoxemic events continued to decrease (from 8.1 events

54 ents, but infants with PH had more prolonged hypoxemic events for desaturations below 80% (7 s vs. 6

55 ata, SWIFT predicts more than 80% and 60% of hypoxemic events in critically ill and COVID-19 patients

56 The numbers of hypoxemic events in the blinded and open arms were 132 a

57 tion frequency, and duration of intermittent hypoxemic events in the week preceding echocardiography

58 Thirty-five percent of all hypoxemic events occurred with completely normal ventila

59 Conclusions: Longer duration of intermittent hypoxemic events was associated both with a diagnosis of

60 18 months of 56.5% in the highest decile of hypoxemic exposure vs 36.9% in the lowest decile (modele

61 nrolled patients who were progressively more hypoxemic; exposure to the prone position was extended f

62 from non-medical use of opioids can lead to hypoxemic/hypercarbic respiratory failure, cardiac arres

63 correlated with the apnea-hypopnea index and hypoxemic indices.

64 ely low birth weight, very low birth weight, hypoxemic ischemic encephalopathy, extracorporeal membra

65 Mild hypoxemic measurements occurred more often in the low-no

66 ical ventilation, in-hospital mortality, and hypoxemic measurements.

67 Studies reporting prone positioning in hypoxemic, nonintubated adult patients with coronavirus

68 Hypoxemic, normoxemic, and AO-induced hyperoxemic blood

69 not improve oxygenation more than placebo in hypoxemic organ donors.

70 31 hypoxemic (Pao2 </= 7.3 kPa) and 63 less hypoxemic (Pao2 > 8.0 kPa) patients with COPD (39% vs. 5

71 OPD cohort, PFO prevalence was similar in 31 hypoxemic (Pao2 </= 7.3 kPa) and 63 less hypoxemic (Pao2

72 error in SpO2 was never enough to classify a hypoxemic patient erroneously as normoxemic or a normoxe

73 oxygen prevents endotracheal reintubation in hypoxemic patients after extubation, compared with Ventu

74 d has not been evaluated in mild-to-moderate hypoxemic patients for whom high-flow nasal cannula oxyg

75 ophageal echocardiography when investigating hypoxemic patients in the intensive care unit, to assess

76 Acute hypoxemic patients with bilateral infiltrates treated wi

77 py improves submaximal exercise tolerance in hypoxemic patients with chronic obstructive pulmonary di

78 Hypoxemic patients with COPD do not have a higher preval

79 cannula, and a demand flow device in 15 male hypoxemic patients with COPD.

80 rtality was lower in mechanically ventilated hypoxemic patients with coronavirus disease 2019 treated

81 uring the COVID-19 pandemic to treat acutely hypoxemic patients with COVID-19 related acute respirato

82 In this large cohort of hypoxemic patients with COVID-19, initiation of HFNO out

83 is frequently applied outside ICU setting in hypoxemic patients with COVID-19.

84 RBCs from hypoxemic patients with elevated pulmonary arterial pres

85 ial oxygen content and oxygen consumption in hypoxemic patients, identify patient subgroups at higher

86 s desaturation during intubation of severely hypoxemic patients, it does not allow for per-procedure

87 prescription of long-term oxygen therapy in hypoxemic patients.

88 Corticosteroids are an important adjunct for hypoxemic patients.

89 e results support APP's use in patients with hypoxemic pneumonia due to COVID-19 infection.

90 The risk of hypoxemic pneumonia increased with age.

91 n about 10% of cases, the infection leads to hypoxemic pneumonia, although it is much more rare in ch

92 All patients were hypoxemic (PO2 64.2 +/- 8.2 mm Hg), and 5 of 21 (24%) we

93 tion by categorizing mechanically ventilated hypoxemic (ratio of Pao2 over the corresponding Fio2 200

94 drome (30.3% vs 8.6%; P = .004) or prolonged hypoxemic respiratory failure (39.4% vs 11.4%; P = .001)

95 lar monocyte and macrophage subsets in acute hypoxemic respiratory failure (AHRF) are poorly understo

96 ndard of care for patients with severe acute hypoxemic respiratory failure (AHRF) caused by COVID-19

97 arch into critically ill patients with acute hypoxemic respiratory failure (AHRF) is growing, how thi

98 extubation readiness in patients with acute hypoxemic respiratory failure (AHRF) may not reflect lun

99 isease-19 (COVID-19) pneumonia induced acute hypoxemic respiratory failure (AHRF), but predictors of

100 o improve oxygenation in children with acute hypoxemic respiratory failure (AHRF), but their roles in

101 s receiving this drug for treatment of acute hypoxemic respiratory failure (AHRF), in order to determ

102 Intubation is a common procedure in acute hypoxemic respiratory failure (AHRF), with minimal evide

103 outcomes of nonintubated patients with acute hypoxemic respiratory failure (AHRF).

104 g the efficiency of clinical trials in acute hypoxemic respiratory failure (HRF) depends on enrichmen

105 ng noninvasive ventilation for de novo acute hypoxemic respiratory failure (i.e., not due to exacerba

106 iratory failure patients (n = 95), and acute hypoxemic respiratory failure (n = 144).

107 Adult patients with acute hypoxemic respiratory failure (n = 320) due to suspected

108 s used ECLS for 100 adults with severe acute hypoxemic respiratory failure (n = 94): paO2/FiO2 ratio

109 acute respiratory infection had more severe hypoxemic respiratory failure (PaO2/FIO2: 106 [66, 160]

110 ad undergone abdominal surgery and developed hypoxemic respiratory failure (partial oxygen pressure <

111 atients with COVID-19 and moderate to severe hypoxemic respiratory failure (ratio of partial pressure

112 judication in three cohorts of patients with hypoxemic respiratory failure (training, internal valida

113 d patients without hypercapnia who had acute hypoxemic respiratory failure and a ratio of the partial

114 r the treatment of large patients with acute hypoxemic respiratory failure and asymmetric lung diseas

115 MERS-CoV causes severe acute hypoxemic respiratory failure and considerable extrapulm

116 s recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in p

117 support in near-term and term newborns with hypoxemic respiratory failure and persistent pulmonary h

118 genation in near-term and term newborns with hypoxemic respiratory failure and persistent pulmonary h

119 brane oxygenation is needed in neonates with hypoxemic respiratory failure and pulmonary hypertension

120 severe end of this spectrum may present with hypoxemic respiratory failure and pulmonary infiltrates,

121 nger, required assisted ventilation, and had hypoxemic respiratory failure as defined by an oxygenati

122 y reveals diffuse bilateral infiltrates, and hypoxemic respiratory failure develops despite appropria

123 apy in children aged 1 to 4 years with acute hypoxemic respiratory failure did not significantly redu

124 h-flow nasal cannula is widely used in acute hypoxemic respiratory failure due to coronavirus disease

125 sk of endotracheal intubation in adults with hypoxemic respiratory failure due to covid-19 but probab

126 espiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.

127 Among patients with acute hypoxemic respiratory failure due to COVID-19, an initia

128 ompared with usual care in adults with acute hypoxemic respiratory failure due to COVID-19.

129 Among patients with hypoxemic respiratory failure following abdominal surger

130 was designed to include patients with acute hypoxemic respiratory failure from all causes.

131 In patients with acute hypoxemic respiratory failure from COVID-19, prone posit

132 cillatory ventilation for treatment of acute hypoxemic respiratory failure in children with diffuse a

133 Acute hypoxemic respiratory failure in immunocompromised patie

134 xygen (HFNO) have been recommended for acute hypoxemic respiratory failure in patients with COVID-19.

135 Among adult patients with acute hypoxemic respiratory failure in the ICU, a lower oxygen

136 Patients with acute hypoxemic respiratory failure in the intensive care unit

137 e of high mortality rate among patients with hypoxemic respiratory failure in the intervention arm (8

138 onary diffusion capacity in ICU survivors of hypoxemic respiratory failure included in this one-year

139 hould be administered in patients with acute hypoxemic respiratory failure is debated.

140 Hypoxemic respiratory failure is one of the leading caus

141 annula (HFNC) therapy in patients with acute hypoxemic respiratory failure is to not delay intubation

142 common reasons for admission to the ICU were hypoxemic respiratory failure leading to mechanical vent

143 ng invasive mechanical ventilation for acute hypoxemic respiratory failure or after thoracic surgery

144 Although pediatric survivors of acute hypoxemic respiratory failure perceive neither a limitat

145 admission to the intensive care unit due to hypoxemic respiratory failure requiring mechanical venti

146 e, nonintubated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplemen

147 tions, was able to support the same level of hypoxemic respiratory failure secondary to acute lung in

148 ents developed inspiratory stridor and acute hypoxemic respiratory failure shortly after the stent wa

149 als but in a higher percent of patients with hypoxemic respiratory failure than reported in these tri

150 stress syndrome (ARDS) is severe, noncardiac hypoxemic respiratory failure that carries a substantial

151 distress syndrome (ARDS) is a form of severe hypoxemic respiratory failure that is characterized by i

152 ALI is a syndrome of acute hypoxemic respiratory failure that is not primarily card

153 cardiovascular conditions and intubation for hypoxemic respiratory failure were associated with a hig

154 Patients with acute hypoxemic respiratory failure were enrolled within 48 ho

155 e hospital mortality for patients with acute hypoxemic respiratory failure who failed NPPV was 64%.

156 on, pulmonary hypertension, and severe acute hypoxemic respiratory failure who underwent endotracheal

157 t of eosinophilic lung disease develop acute hypoxemic respiratory failure with a rapid response to t

158 ritical illness syndrome consisting of acute hypoxemic respiratory failure with bilateral pulmonary i

159 apy in children aged 1 to 4 years with acute hypoxemic respiratory failure without bronchiolitis is u

160 ng noninvasive ventilation for de novo acute hypoxemic respiratory failure, and a high expired tidal

161 sing for making advances in pneumonia, acute hypoxemic respiratory failure, and acute respiratory dis

162 l of nonintubated patients with COVID-19 and hypoxemic respiratory failure, daily APP of 6 hours show

163 who require mechanical ventilation for acute hypoxemic respiratory failure, further reduction in tida

164 bation.Conclusions: As compared with HFNC in hypoxemic respiratory failure, helmet NIV improves oxyge

165 in ABI patients, including among those with hypoxemic respiratory failure, highlighting potential op

166 In 217 children with acute hypoxemic respiratory failure, initial end-tidal alveola

167 s receiving mechanical ventilation for acute hypoxemic respiratory failure, of a planned sample size

168 ot in patients with post-extubation failure, hypoxemic respiratory failure, or end-stage cancer.

169 Among patients with hypoxemic respiratory failure, PEEP remained significant

170 -Vt ventilation strategies in ARDS and acute hypoxemic respiratory failure, the posterior probability

171 Objectives: To measure, in patients with hypoxemic respiratory failure, the probability of invasi

172 Among patients with acute hypoxemic respiratory failure, the use of extracorporeal

173 In patients with nonhypercapnic acute hypoxemic respiratory failure, treatment with high-flow

174 lysis of trials of adult patients with acute hypoxemic respiratory failure, treatment with noninvasiv

175 age and within 72 h of intubation for acute hypoxemic respiratory failure, were enrolled.

176 d nitric oxide in the premature newborn with hypoxemic respiratory failure.

177 nt for intensive care in children with acute hypoxemic respiratory failure.

178 ane oxygenation in term neonates with severe hypoxemic respiratory failure.

179 n clinical outcome in neonatal patients with hypoxemic respiratory failure.

180 tric oxide (NO) in four patients with severe hypoxemic respiratory failure.

181 of ventilator support in children with acute hypoxemic respiratory failure.

182 years requiring hospital admission for acute hypoxemic respiratory failure.

183 pitalized adults with COVID-19-related acute hypoxemic respiratory failure.

184 istress syndrome on day 1 and day 2 of acute hypoxemic respiratory failure.

185 is increasingly used in patients with acute hypoxemic respiratory failure.

186 s usual care in adults with covid-19 related hypoxemic respiratory failure.

187 ients with coronavirus diseases 2019-related hypoxemic respiratory failure.

188 tients were placed on VV ECMO for refractory hypoxemic respiratory failure.

189 (n = 51, 82%) was the main etiology of acute hypoxemic respiratory failure.

190 -aged patients and is associated with severe hypoxemic respiratory failure.

191 oxygen therapy alone in patients with acute hypoxemic respiratory failure.

192 d conditions and presented with acute severe hypoxemic respiratory failure.

193 Mechanical ventilation was begun for hypoxemic respiratory failure.

194 al fibrosis with decreasing lung volumes and hypoxemic respiratory failure.

195 is established therapy for term infants with hypoxemic respiratory failure.

196 th high hospital mortality for patients with hypoxemic respiratory failure.

197 aled nitric oxide in premature newborns with hypoxemic respiratory failure.

198 ailure patients, and 86% in 57 patients with hypoxemic respiratory failure.

199 c signature in children with pediatric acute hypoxemic respiratory failure. Seventy-four immunocompet

200 n (NIV) are used for the management of acute hypoxemic respiratory failure.Objectives: Physiological

201 All the patients were admitted for hypoxemic respiratory failure; 75% (18 patients) needed

202 ention groups for the COVID-19 patients with hypoxemic respiratory failure; however, more evidence is

203 hough variable, usually includes progressive hypoxemic respiratory insufficiency and, in some patient

204 onia with pleural effusion and clinically as hypoxemic respiratory insufficiency.

205 9 (COVID-19) pneumonia admitted in the early hypoxemic stage.

206 S, 25 cirrhotic patients without HPS, and 15 hypoxemic subjects with intrinsic lung disease alone.

207 Fibrin deposition is a salient feature of hypoxemic vasculature and results from induction of tiss